JARED PROBST: Open Payments
NPI 1346295177 · SALT LAKE CITY, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,308 in 126 payments from 27 companies in 2025. Trend: 2023 $2,209 · 2024 $3,319 · 2025 $2,308
Food & beverage: $2,308
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $501 |
| PFIZER INC. | 21 | $264 |
| Amgen Inc. | 14 | $191 |
| Gilead Sciences, Inc. | 9 | $144 |
| Corcept Therapeutics | 6 | $137 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $102 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $88 |
| Novo Nordisk Inc | 5 | $84 |
| Astellas Pharma US Inc | 5 | $82 |
| GlaxoSmithKline, LLC. | 4 | $73 |
Products named: VRAYLAR, NURTEC ODT, Korlym, OTEZLA, UBRELVY, CAPLYTA, Veozah, QULIPTA.
Industry payments across UT — which companies pay providers there.
